Endurant Capital Management LP Clovis Oncology, Inc. Transaction History

Endurant Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $895,785 - $1.51 Million	-30,500 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $109,356 - $162,240	-2,600 Reduced 7.85%	30,500 $1.39 Million
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $1.73 Million - $2.34 Million	-34,550 Reduced 51.07%	33,100 $1.75 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $628,821 - $921,922	10,900 Added 19.21%	67,650 $4.6 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $3.81 Million - $4.81 Million	56,750	56,750 $4.68 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.